UK Markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
At close: 12:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5000
Open6.7500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.5000 - 2.5000
52-week range2.5000 - 26.6900
Volume3
Avg. volume287
Market cap224.462M
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-0.6550
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Silence Therapeutics to Present at Jefferies Healthcare Conference

    LONDON, June 02, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT.

  • Business Wire

    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

    LONDON, May 18, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.

  • Business Wire

    Silence Therapeutics Reports First Quarter 2022 Results

    LONDON, May 16, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.